2024-02-08
Background: The use of monoclonal antibodies has changed the treatment of several immune-mediated inflammatory diseases, including psoriasis. However, these large proteins must be administered by injection. JNJ-77242113 is a novel, orally administered interleukin-23-receptor antagonist peptide that selectively blocks interleukin-23 signaling and downstream cytokine production.
Do not miss out on valuable insights and research updates. Join our scientific community today!
3530 Saint-Laurent Boulevard
Suite 300
Montreal, QC, H2X 2V1, Canada
© 2025 Indero. All Rights Reserved. Privacy Policy. Designed and developed by Altitude Marketing.
Our long-standing relationships with key opinion leaders and highly performing sites result in optimized start-up processes that deliver strong results in the least amount of time. As part of our site evaluation, our team utilizes past performance metrics, recruitment projections based on the competitive landscape, and detailed feasibility surveys to determine a site’s capabilities and interest in a study.
Our dedicated patient recruitment and advertising team integrates with the study team to tailor recruitment strategies, customize central ad campaigns, develop advertising creative, and continuously track and adapt recruitment goals. Our patient-centric approach is enhanced by Clinago, our technology enabled recruitment service.
We orchestrate all study activities and deliverables, including the site selection process, budget and contract negotiations, patient engagement, and recruitment enrollment projections, all while respecting your study timelines.
We orchestrate all study activities and deliverables, including the site selection process, budget and contract negotiations, patient engagement, and recruitment enrollment projections, all while respecting your study timelines.
